BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20417192)

  • 1. Aldose reductase inhibition ameliorates the detrimental effect of estrogen replacement therapy on neuropathology in diabetic rats subjected to transient forebrain ischemia.
    Shen B; Vetri F; Mao L; Xu HL; Paisansathan C; Pelligrino DA
    Brain Res; 2010 Jun; 1342():118-26. PubMed ID: 20417192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen replacement therapy in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules via a RAGE-related process.
    Xu HL; Vetri F; Lee HK; Ye S; Paisansathan C; Mao L; Tan F; Pelligrino DA
    Am J Physiol Heart Circ Physiol; 2009 Dec; 297(6):H2059-67. PubMed ID: 19820198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia.
    Xu HL; Salter-Cid L; Linnik MD; Wang EY; Paisansathan C; Pelligrino DA
    J Pharmacol Exp Ther; 2006 Apr; 317(1):19-29. PubMed ID: 16339390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen replacement treatment in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules.
    Xu HL; Baughman VL; Pelligrino DA
    Stroke; 2004 Aug; 35(8):1974-8. PubMed ID: 15232125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of estrogen on leukocyte adhesion after transient forebrain ischemia.
    Santizo RA; Anderson S; Ye S; Koenig HM; Pelligrino DA
    Stroke; 2000 Sep; 31(9):2231-5. PubMed ID: 10978057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of benefit from estrogen replacement therapy in diabetic ovariectomized female rats subjected to transient forebrain ischemia.
    Santizo RA; Xu HL; Ye S; Baughman VL; Pelligrino DA
    Brain Res; 2002 Nov; 956(1):86-95. PubMed ID: 12426050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV; Vyas VK; Goyal RK
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ischemic postconditioning during reperfusion attenuates oxidative stress and intestinal mucosal apoptosis induced by intestinal ischemia/reperfusion via aldose reductase.
    Wen SH; Ling YH; Li Y; Li C; Liu JX; Li YS; Yao X; Xia ZQ; Liu KX
    Surgery; 2013 Apr; 153(4):555-64. PubMed ID: 23218881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong inhibition of the polyol pathway diverts glucose flux to protein glycation leading to rapid establishment of secondary complications in diabetes mellitus.
    Jagdale AD; Bavkar LN; More TA; Joglekar MM; Arvindekar AU
    J Diabetes Complications; 2016 Apr; 30(3):398-405. PubMed ID: 26896333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia.
    Zhang T; Wu J; Yao X; Zhang Y; Wang Y; Han Y; Wu Y; Xu Z; Lan J; Han S; Zou H; Sun Q; Wang D; Zhang J; Wang G
    Mol Neurobiol; 2023 Jul; 60(7):3741-3757. PubMed ID: 36940077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined endothelial nitric oxide synthase upregulation and caveolin-1 downregulation decrease leukocyte adhesion in pial venules of ovariectomized female rats.
    Santizo RA; Xu HL; Galea E; Muyskens S; Baughman VL; Pelligrino DA
    Stroke; 2002 Feb; 33(2):613-6. PubMed ID: 11823678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More severe type 2 diabetes-associated ischemic stroke injury is alleviated in aldose reductase-deficient mice.
    Yeung CM; Lo AC; Cheung AK; Chung SS; Wong D; Chung SK
    J Neurosci Res; 2010 Jul; 88(9):2026-34. PubMed ID: 20143423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide synthase inhibitor augments post-ischemic leukocyte adhesion in the cerebral microcirculation in vivo.
    Hudetz AG; Wood JD; Kampine JP
    Neurol Res; 1999 Jun; 21(4):378-84. PubMed ID: 10406010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats.
    Shimoshige Y; Minoura K; Matsuoka N; Takakura S; Mutoh S; Kamijo M
    Brain Res; 2009 Jan; 1247():182-7. PubMed ID: 18992730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Ashizawa N; Yoshida M; Sugiyama Y; Akaike N; Ohbayashi S; Aotsuka T; Abe N; Fukushima K; Matsuura A
    Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol.
    Sampath C; Sang S; Ahmedna M
    Biomed Pharmacother; 2016 Dec; 84():502-513. PubMed ID: 27685794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.